Drugs / Cardioplegia Solution
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT05076604 Comparator | Mar 2019 → Jun 2023 | aortic valve disorder, mitral valve disorder | Washington University School of Medicine | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cardioplegia Solution | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05076604 ↗ |
| Route | Intravenous | “4:1 cardioplegia consists of 4 parts crystalloid intravenous fluid to one part human blood.” NCT05076604 ↗ |